January-March
· Total revenue of
· EBITA[1] was
· Earnings per share (EPS) of
· Net debt[1] of
· Elocta® sales were
· Sales for Gamifant® amounted to
· Sobi initiated a short-term clinical study with anakinra and emapalumab as potential treatments for hyperinflammatory and cytokine storm syndrome related to severe COVID-19
Outlook 2020[2] - unchanged
Outlook for full-year 2020 of revenue in the range of
Financial Summary
[][][][][][][][][][]
Q1 Q1 Full-year
Amounts in SEK M 2020 2019 Change 2019
Total revenue 4,639 3,265 42% 14,248
Gross profit 3,598 2,494 44% 10,913
Gross margin[1] 78% 76% 77%
EBITA[1] 2,173 1,509 44% 5,933
EBITA adjusted[1,3] 2,173 1,471 48% 6,145
EBITA margin[1] 47% 46% 42%
EBITA margin 47% 45% 43%
adjusted[1,3]
Profit for the 1,182 903 31% 3,304
period
Earnings per share, 4.02 3.14 28% 11.29
SEK
Earnings per share, 4.02 3.03 32% 11.89
SEK adjusted[1,3,4]
[1]Alternative
Performance
Measures (APMs).
[2]At current
exchange rates as
of 13 February
2020.
[3]EBITA Full-year
2019 excluding non
-recurring items;
transaction costs
related to the
acquisition of Dova
in Q4 of
restructuring costs
of
2019 and gain from
divestment of
SOBI005 in Q1 2019
of
[4]EPS Full-year
2019 excluding
impairment of
intangible assets
of
to restructuring in
Q2 2019.
"Total revenue for the first quarter 2020 was
Telephone conference:
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the Q1 results, today at
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 505 583 58
US: +1 646 722 4904
Click here to go to the live webcast. (https://event.on24.com/wcc/r/2240995/55545884168582382127B8C51164F686)
After the live event the webcast will be available on-demand via the same URL.
---
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, Sobi employs approximately 1,400 people across
For more information please contact
Paula Treutiger, Head of Communication & Investor Relations
+ 46 733 666 599
paula.treutiger@sobi.com
+ 46 708 734 095
linda.holmstrom@sobi.com
This information is information that
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-report-for-the-first-quarter-2020,c3099740
https://mb.cision.com/Main/14266/3099740/1238399.pdf
(c) 2020 Cision. All rights reserved., source